'Despite US Slowdown, Indian Pharma Sector To See Steady FY26 Growth,' Says ICRA Report
Ratings agency ICRA, in a report, said that global headwinds and regulatory uncertainties cast a shadow over its largest export market in the US, but 8-10 per cent growth is expected in the domestic market, with 10-12 per cent growth in Europe.

The Indian pharmaceutical sector is expected to achieve 7-9 per cent revenue growth in FY 2026. | File Image
New Delhi: The Indian pharmaceutical sector is expected to achieve 7-9 per cent revenue growth in FY 2026, driven by strong domestic and European demand, despite a significant slowdown in its US market, a report said on Thursday.
Ratings agency ICRA, in a report, said that global headwinds and regulatory uncertainties cast a shadow over its largest export market in the US, but 8-10 per cent growth is expected in the domestic market, with 10-12 per cent growth in Europe.
The operating profit margins of the companies are expected to remain resilient at 24-25 per cent in FY26, broadly in line with 24.6 per cent in FY25, aided by favourable raw material prices, improved operating leverage, and a rising share of specialty products.
US revenues are anticipated to moderate with YoY growth slowing 3-5 per cent from nearly 10 per cent in FY 2025, the report said.
ALSO READ
“ICRA’s sample set companies recorded 10.3 per cent YoY growth in Q1 FY26, driven by market share gains in chronic therapies, new product introductions, and regular price hikes -- despite subdued volume growth for branded generics, partly due to rising genericisation,” said Kinjal Shah, Senior Vice President & Co-Group Head, ICRA.
ICRA maintained a 'stable' outlook on the sector due to its steady revenue growth and earnings trajectory, underpinned by healthy balance sheets, strong liquidity, and robust operating profit margins (OPM).
The ratings agency said that domestic drug sales are boosted by sales force expansion, improved productivity of medical representatives, deeper rural distribution, new product launches, and recent GST exemptions on lifesaving drugs.
Research and development (R&D) spending is projected to remain steady at 6-7 per cent of revenues, with companies increasingly focusing on complex molecules and specialty products over generics.
(Except for the headline, this article has not been edited by FPJ's editorial team and auto-generated from an agency feed.)
RECENT STORIES
-
'Not Just A Car But Years Of Hard Work': Pune Man Refuses To Let Go Of His Tata Nexon EV In... -
'Free Press Vatika' Launched At Pitra Parvat To Support Indore’s 21 Lakh Plantation Drive— VIDEO -
Iran President Masoud Pezeshkian Accuses US Of ‘Bending Rules’ Amid FIFA World Cup 2026... -
XAT 2027 Registration To Open On July 15 At xatonline.in; Early Applicants To Get First Preferred... -
MP's Dhindori Collector Hears Public Grievances & Orders Time-Bound Redressal
